Clinical Trials Logo

Pediatric Hodgkin Lymphoma clinical trials

View clinical trials related to Pediatric Hodgkin Lymphoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05455268 Completed - Clinical trials for Pediatric Acute Myeloid Leukemia

Information Support Using an Online Learning Platform for Malaysian Pediatric Leukemia and Lymphoma Parents

eHOPE
Start date: July 15, 2022
Phase: N/A
Study type: Interventional

This is a study protocol to determine whether it is feasible to support parents of children with blood cancers by providing information over an online learning platform. This study will be conducted in Malaysia. An online learning platform will be used to provide information relevant to parents who care for children diagnosed with leukemia or lymphoma. The use of this platform will be compared with current usual care, where only verbal discussions and ad hoc caregiver training is provided to support these parents, based on the clinician's judgement. Participants knowledge and confidence level in caregiving as well as coping will be compared between the two groups. To determine the feasibility of this method of information support, the researchers will also obtain feedback from participants who used the online learning platform and determine whether there are many who drop out from using it. The findings will determine whether use of online learning platform is suitable to deliver information support for parents, in view of currently limited resources for supportive care in childhood cancer care in Malaysia.

NCT ID: NCT04213209 Completed - Clinical trials for Peripheral T Cell Lymphoma

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

Start date: December 31, 2019
Phase:
Study type: Observational

The purpose of this survey is to examine the safety of adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with relapsed or refractory CD30-positive PTCL or Hodgkin lymphoma (HL) in the actual use of on concomitant Brentuximab Vedotin in routine clinical practice.